Kahn Brothers Group Inc. Buys New Holdings in Organon & Co. $OGN

Kahn Brothers Group Inc. purchased a new position in Organon & Co. (NYSE:OGN) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 2,670,523 shares of the company’s stock, valued at approximately $36,159,000. Organon & Co. makes up 0.1% of Kahn Brothers Group Inc.’s holdings, making the stock its 17th largest holding.

Several other hedge funds and other institutional investors also recently bought and sold shares of OGN. Farther Finance Advisors LLC lifted its stake in Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after acquiring an additional 2,033 shares during the period. Allied Private Wealth LLC purchased a new position in shares of Organon & Co. during the second quarter worth $33,000. Eurizon Capital SGR S.p.A. acquired a new position in Organon & Co. during the fourth quarter valued at $44,000. Kestra Advisory Services LLC acquired a new position in Organon & Co. during the fourth quarter valued at $47,000. Finally, WNY Asset Management LLC purchased a new stake in Organon & Co. in the first quarter valued at $64,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Trading Down 0.0%

Organon & Co. stock opened at $13.77 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.44 and a debt-to-equity ratio of 8.43. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.77. The stock’s 50 day simple moving average is $13.58 and its two-hundred day simple moving average is $11.07. The firm has a market cap of $3.61 billion, a PE ratio of 17.88, a P/E/G ratio of 1.27 and a beta of 1.55.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.’s payout ratio is currently 10.39%.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.